22 patents
Utility
ANTI-ROR1 Antibody and ROR1-TARGETING Engineered Cells
30 Nov 23
The present invention is directed to a monoclonal mouse or humanized ROR1 antibody, or a single-chain variable fragment (scFv).
Vita Golubovskaya, Lijun Wu
Filed: 22 May 23
Utility
Crispr Abasic Restricted Nucleotides and Crispr Accuracy Via Analogs
3 Nov 22
The present disclosure provides polynucleotide guides for use in CRISPR-Cas systems wherein such polynucleotides contain at least one CRISPR abasic restricted nucleotide (CABRNT) and/or at least one CRISPR accuracy via analogs (CAVA) nucleotide.
Paul Daniel DONOHOUE, Matthew John IRBY
Filed: 8 Dec 20
Utility
Compositions and Methods of Nucleic Acid-targeting Nucleic Acids
8 Sep 22
This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
Andrew Paul MAY, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
Filed: 20 Aug 21
Utility
Humanized Bcma Antibody and Bcma-car-t Cells
14 Jul 22
Lijun Wu, Vita Golubovskaya
Filed: 21 Mar 22
Utility
Humanized Bcma Antibody and Bcma-car-t Cells
20 Jan 22
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
LIJUN WU, VITA GOLUBOVSKAYA
Filed: 4 Oct 21
Utility
Crispr Hybrid Dna/rna Polynucleotides and Methods of Use
2 Dec 21
The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
Andrew Paul MAY, Paul Daniel DONOHOUE
Filed: 22 Mar 21
Utility
Bcma-car-natural Killer (NK) Cells and Methods Related Thereto
9 Sep 21
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
LIJUN WU, VITA GOLUBOVSKAYA
Filed: 21 May 21
Utility
Suicide Module Compositions and Methods
15 Jul 21
Chimeric transmembrane proteins comprising one or more suicide modules and methods of making and using these constructs are disclosed.
Katharina F.S. Stengel
Filed: 30 Sep 19
Utility
Modified Cascade Ribonucleoproteins and Uses Thereof
10 Jun 21
A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cash which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity.
Stan Johan Jozef Brouns, John van der Oost
Filed: 18 Feb 21
Utility
Humanized Bcma Antibody and Bcma-car-t Cells
27 May 21
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
Lijun Wu, Vita Golubovskaya
Filed: 13 Jan 21
Utility
Engineered Cascade Components and Cascade Complexes
8 Apr 21
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Scott David Gradia, Sanne Eveline Klompe, Samuel Henry Sternberg, Matthew Scott Thompson
Filed: 11 Dec 20
Utility
Modified Lymphocytes
6 Jan 21
Modified lymphocytes that ectopically express an endogenous gene of interest, such as a gene encoding a chemokine cell surface receptor, are described.
Katharina F.S. Stengel
Filed: 3 Dec 18
Utility
Engineered Cascade Components and Cascade Complexes
6 Jan 21
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Filed: 20 Sep 20
Utility
Humanized Bcma Antibody and Bcma-car-t Cells
23 Dec 20
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
LIJUN Wu, Vita Golubovskaya
Filed: 1 Sep 20
Utility
Modified Cascade Ribonucleoproteins and Uses Thereof
14 Oct 20
A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity.
Stan Johan Jozef Brouns, John van der Oost
Filed: 25 Jun 20
Utility
Engineered Nucleic-Acid Targeting Nucleic Acids
7 Oct 20
The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 18 Jun 20
Utility
Engineered Cascade Components and Cascade Complexes
2 Sep 20
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Filed: 18 Mar 20
Utility
Engineered Nucleic Acid-targeting Nucleic Acids
1 Jul 20
The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 10 Mar 20
Utility
Novel Crispr-associated (Cas) Protein
11 Mar 20
A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering.
Matthew Merrill Carter, Paul Daniel Donohoue
Filed: 21 Nov 19
Utility
Engineered Nucleic-Acid Targeting Nucleic Acids
4 Mar 20
The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 17 Nov 19